Patent ID: 11952585
Assignee: HOMOLOGY MEDICINES, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 13:
14. The method of claim 12, wherein:
if the subject exhibits a level of a liver transaminase that is at least about 2 times the upper limit of normal (ULN) at any time during the sequential dosing regimen, the sequential dosing regimen will be restarted from step (1); or
if the subject exhibits a level of a liver transaminase that is at least about 2 times ULN after completion of step (6), the subject is further administered the first immunosuppressant according to the following sequential dosing regimen:
(7) 60 mg/day in prednisolone equivalents for two to four weeks;
(8) 40 mg/day in prednisolone equivalents for two weeks;
(9) 30 mg/day in prednisolone equivalents for two weeks;
(10) 20 mg/day in prednisolone equivalents for two weeks;
(11) 10 mg/day in prednisolone equivalents for two weeks; and
(12) 5 mg/day in prednisolone equivalents for two weeks.